A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, CROSSOVER STUDY TO DETERMINE THE BE OF NIRMATRELVIR FOLLOWING ORAL ADMINISTRATION OF FDC TABLETS RELATIVE TO THE PAXLOVID® COMMERCIAL TABLETS IN HEALTHY ADULT PARTICIPANTS UNDER FASTED CONDITIONS

Medicines that may have different names or be made in different ways but have the same effect on the body are called bioequivalent.
The purpose of this study is to learn about the bioequivalence of nirmatrelvir plus ritonavir after taking 2 different combination tablet forms by mouth. These combination tablets are compared to the tablet formulation that is already in the market. This study will be done under fasted conditions in healthy adult participants.
This study is seeking participants who are:
Male and non-pregnant female participants aged 18 years and above.
with a body weight of more than 50 kilograms and Body Mass Index (BMI) between 16 to 32 kilograms per meter squared.
are healthy as confirmed by medical history, physical examination, laboratory tests.
The study will also look at the safety and tolerability of nirmatrelvir plus ritonavir combination tablet and marketed tablet formulations in healthy adult participants.
The study will consist of 4 treatments:
Treatment A: Single oral dose of nirmatrelvir plus ritonavir 150 (1 × 150)/100 milligrams marketed tablets under fasted conditions (Reference 1) Treatment B (low dose strength): Single oral dose of nirmatrelvir plus ritonavir 150/100 milligrams (2 × [75/50 milligrams]) combination tablets under fasted conditions (Test 1) Treatment C: Single oral dose of nirmatrelvir/ritonavir 300 (2 × 150)/100 milligrams marketed tablets under fasted conditions (Reference 2) Treatment D (high dose strength): Single oral dose of nirmatrelvir/ritonavir 300/100 milligrams (2 × [150/50 milligrams]) combination tablets under fasted conditions (Test 2)
All treatments will be given under fasted conditions. Fasted condition means the participants would not have had anything to eat before taking the medicines.
Around 28 participants will be enrolled in the study. Healthy participants will be tested to see if they can be in the study within 28 days before receiving the study medicine. Selected participants will be admitted to the clinical research unit (CRU) one day before receiving the study medicine and will remain in the CRU until discharge after completing all the treatment periods.
On Day 1 of each period, participants will be given a single dose of study medicine nirmatrelvir/ritonavir 300/100 mg or 150/100 mg by mouth by chance. Study medicine will be given with approximately 240 milliliters of room temperature water under fasted conditions (overnight fast of at least 10 hours and no food until 4 hours after receiving the study medicine). Blood samples will be collected at different times of the day up to 48 hours after taking the study medicine. Participants will be discharged from the CRU on Day 3 of Period 4, after all the study related procedures have been completed.
A follow-up call will be made to participants around 28 to 35 days from receiving the final dose of the study medicine. The study will look at the experiences of participants receiving the study medicine. This will help to understand if the study medicine is safe and effective.

开始日期2025-02-14

申办/合作机构

Pfizer Inc.

NCT05997485 / WithdrawnN/A

A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics Among COVID-19 Patients Receiving Treatment With Nirmatrelvir/Ritonavir (PAXLOVIDTM) in Morocco.

The purpose of this study is to collect information on the:
general information of a group of people such as their age, sex, and other facts.
clinical information of the patients such as any other illness before having COVID 19.
In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment.
This study will be conducted in Morocco. The study will capture information of the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment. The inpatients will be admitted in the hospital for other reasons than COVID-19.
This study will have about 150 patients. The study will involve collection of patient information from medical records. The information collected can be either from papers or from computers.
The study will include patient information of those who:
are confirmed to have COVID-19 infection during the study period from 01 June 2022 to 30 June 2023.
are 18 years of age or older.
are prescribed Nirmatrelvir and ritonavir. This study will help to inform decision-making on use of Paxlovid at the national level.

开始日期2024-03-30

申办/合作机构

Pfizer Inc.

NCT06291831 / CompletedN/A

A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics and Healthcare Resource Use (HRU) Among COVID-19 Patients With or Without Nirmatrelvir/Ritonavir (PAXLOVID™) Treatment in the Kingdom of Bahrain.

The purpose of this study is to collect information on the:
general information of a group of people such as their age, sex
clinical information of the patients such as any other illness before having COVID 19.
the number of COVID-19 patients who meet and follow the most up to date World Health Organization (WHO) recommendations for medication to treat COVID-19 (such as version 14, published 10Nov2023) compared to Kingdom of Bahrain national recommendations
adult COVID-19 patients' health care resource use and outcomes within the 28-day period In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment.
This study will be conducted in the Kingdom of Bahrain. The study will capture information of the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment and those not treated with nirmatrelvir, ritonavir.
This study will have about 3000 patients treated with Paxlovid™ therapy and 1000 were not. The study will involve collection of patient information from medical records. The information collected can be either from papers or from computers.
The study will include patient information of those who:
had COVID-19 infection during the study period from 16 February 2022 to 30 November 2022.
are 18 years of age or older. This study will help to inform decision-making on use of Paxlovid at the national level.

开始日期2024-03-13

申办/合作机构

Pfizer Inc.

100 项与奈玛特韦/利托那韦相关的临床结果

登录后查看更多信息

100 项与奈玛特韦/利托那韦相关的转化医学

登录后查看更多信息

100 项与奈玛特韦/利托那韦相关的专利（医药）

登录后查看更多信息

375

项与奈玛特韦/利托那韦相关的文献（医药）

2024-04-10·Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses

Review

作者: Meyerowitz, Eric A ; Li, Yijia

Abstract:

The goals of coronavirus disease 2019 (COVID-19) antiviral therapy early in the pandemic were to prevent severe disease, hospitalization, and death. As these outcomes have become infrequent in the age of widespread population immunity, the objectives have shifted. For the general population, COVID-19–directed antiviral therapy should decrease symptom severity and duration and minimize infectiousness, and for immunocompromised individuals, antiviral therapy should reduce severe outcomes and persistent infection. The increased recognition of virologic rebound following ritonavir-boosted nirmatrelvir (NMV/r) and the lack of randomized controlled trial data showing benefit of antiviral therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for standard-risk, vaccinated individuals remain major knowledge gaps. Here, we review data for selected antiviral agents and immunomodulators currently available or in late-stage clinical trials for use in outpatients. We do not review antibody products, convalescent plasma, systemic corticosteroids, IL-6 inhibitors, Janus kinase inhibitors, or agents that lack Food and Drug Administration approval or emergency use authorization or are not appropriate for outpatients.

2024-04-01·Journal of peptide science : an official publication of the European Peptide Society

Antiviral peptides inhibiting the main protease of SARS‐CoV‐2 investigated by computational screening and in vitro protease assay

Article

作者: Stewart, James ; Sufian, Md Abu ; McShan, Andrew C ; Faddis, Ryan ; Jia, Ruoqing ; Rupa, Sharmin Akther ; Shahinuzzaman, A D A ; Rahman, Khondaker Miraz ; Bourque, Cole ; Al-Adhami, Taha ; Islam, Rajib ; Halim, Mohammad A ; Ali, Md Ackas ; Stone, Kaylee ; Shawon, Jakaria ; Williams, Blaise

The main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) plays an important role in viral replication and transcription and received great attention as a vital target for drug/peptide development. Therapeutic agents such as small‐molecule drugs or peptides that interact with the Cys–His present in the catalytic site of Mpro are an efficient way to inhibit the protease. Although several emergency‐approved vaccines showed good efficacy and drastically dropped the infection rate, evolving variants are still infecting and killing millions of people globally. While a small‐molecule drug (Paxlovid) received emergency approval, small‐molecule drugs have low target specificity and higher toxicity. Besides small‐molecule drugs, peptide therapeutics are thus gaining increasing popularity as they are easy to synthesize and highly selective and have limited side effects. In this study, we investigated the therapeutic value of 67 peptides targeting Mpro using molecular docking. Subsequently, molecular dynamics (MD) simulations were implemented on eight protein–peptide complexes to obtain molecular‐level information on the interaction between these peptides and the Mpro active site, which revealed that temporin L, indolicidin, and lymphocytic choriomeningitis virus (LCMV) GP1 are the best candidates in terms of stability, interaction, and structural compactness. These peptides were synthesized using the solid‐phase peptide synthesis protocol, purified by reversed‐phase high‐performance liquid chromatography (RP‐HPLC), and authenticated by mass spectrometry (MS). The in vitro fluorometric Mpro activity assay was used to validate the computational results, where temporin L and indolicidin were observed to be very active against SARS‐CoV‐2 Mpro with IC50 values of 38.80 and 87.23 μM, respectively. A liquid chromatography–MS (LC–MS) assay was developed, and the IC50 value of temporin L was measured at 23.8 μM. The solution‐state nuclear magnetic resonance (NMR) structure of temporin L was determined in the absence of sodium dodecyl sulfate (SDS) micelles and was compared to previous temporin structures. This combined investigation provides critical insights and assists us to further develop peptide inhibitors of SARS‐CoV‐2 Mpro through structural guided investigation.

2024-03-01·Journal of molecular graphics & modelling

Discovery of pyrimidoindol and benzylpyrrolyl inhibitors targeting SARS-CoV-2 main protease (Mpro) through pharmacophore modelling, covalent docking, and biological evaluation

Article

作者: Rabeh, Wael M ; Atatreh, Noor ; Mohamed, Feda E ; Mahgoub, Radwa E ; Ferreira, Juliana ; Ali, Bassam R ; Ghattas, Mohammad A

The main protease (M^pro) enzyme has an imperative function in disease progression and the life cycle of the SARS-CoV-2 virus. Although the orally active drug nirmatrelvir (co-administered with ritonavir as paxlovid) has been approved for emergency use as the frontline antiviral agent, there are a number of limitations that necessitate the discovery of new drug scaffolds, such as poor pharmacokinetics and susceptibility to proteolytic degradation due to its peptidomimetic nature. This study utilized a novel virtual screening workflow that combines pharmacophore modelling, multiple-receptor covalent docking, and biological evaluation in order to find new M^pro inhibitors. After filtering and analysing ∼66,000 ligands from three different electrophilic libraries, 29 compounds were shortlisted for experimental testing, and two of them exhibited ≥20% inhibition at 100 μM. Our top candidate, GF04, is a benzylpyrrolyl compound that exhibited the highest inhibition activity of 38.3%, with a relatively small size (<350 Da) and leadlike character. Interestingly, our approach also identified another hit, DR07, a pyrimidoindol with a non-peptide character, and a molecular weight of 438.9 Da, reporting an inhibition of 26.3%. The established approach detailed in this study, in conjunction with the discovered inhibitors, has the capacity to yield novel perspectives for devising covalent inhibitors targeting the COVID-19 M^pro enzyme and other comparable targets.

1,368

项与奈玛特韦/利托那韦相关的新闻（医药）

2024-08-28

·PRNewswire

Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization

"Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" "While maintaining the current process for emergency use authorization for mild-to-moderate COVID-19 patients, Hyundai Bioscience will expedite Phase 3 clinical trial exclusively for high-risk group" SEOUL, South Korea, Aug. 28, 2024 /PRNewswire/ -- Hyundai Bioscience Co., Ltd, currently pursuing Emergency Use Authorization (EUA) for its oral COVID-19 treatment, Xafty®, for mild-to-moderate cases, announced on August 27th that it has submitted an Investigational New Drug (IND) application for Phase 3 clinical trial to the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea. This new trial will specifically target high-risk group patients with mild-to-moderate COVID-19. The high-risk group includes those aged 60 and above, adults over 19 with underlying conditions such as diabetes, hypertension, cardiovascular disease, chronic heart, and lung diseases, or immunocompromised individuals. These patients are at a higher risk of developing severe complications if infected with COVID-19, making them a higher priority group for global health authorities. As COVID-19 cases surge again recently, the number of confirmed cases and hospitalizations is rapidly increasing. Among hospitalized patients, over 65% are aged 65 or older. Despite the rising number of high-risk group patients and hospitalizations, there are currently limited treatment options worldwide that can be safely prescribed to this high-risk group. Existing COVID-19 treatments are known to have drug interactions, making them unsuitable for patients already taking contraindicated medications and thus limiting their effectiveness. There is an urgent need for a treatment that can be safely prescribed to high-risk group without such concerns. In response, the U.S. National Institutes of Health (NIH) conducted a global Phase 3 clinical trial of a Japanese COVID-19 treatment aimed at high-risk group patients who cannot take Paxlovid®, but the trial failed to meet its primary endpoints. This situation makes Xafty® the only remaining possible option. Hyundai Bioscience promptly began preparations for a Phase 3 study targeting the high-risk group following the NIH's announcement of the Japanese treatment's clinical results. Xafty® has already demonstrated its efficacy and safety in a previous clinical trial involving 300 mild-to-moderate COVID-19 patients, where it demonstrated rapid improvement in all 12 symptoms. In particular, a separate statistical analysis requested by the Korea Disease Control and Prevention Agency (KDCA) on high-risk group patients revealed that Xafty® was even more effective for high-risk group who were on other medications for conditions such as diabetes, hypertension, and heart disease. Based on these promising results, Hyundai Bioscience has decided to move forward with an additional Phase 3 clinical study focused on high-risk COVID-19 patients. The number of participants will be significantly increased from the previous 120 (40 each in the low-dose, high-dose, and control groups) to 290 participants (145 each in the test and control groups). Unlike previous trials that required hospitalization of all participants, this trial will involve outpatient visits only, allowing faster recruitment and significant cost savings—estimated at 20% to 25% less per patient compared to the previous study. Dr. Geun-Woo Jin, Executive Vice President of Hyundai Bioscience, stated, "While Paxlovid® is available for high-risk patients, those who are taking contraindicated medications cannot be prescribed Paxlovid®, leaving them in a treatment blind spot. The Japanese COVID-19 treatment, developed under the NIH's lead for high-risk patients, failed to clear the Phase 3 hurdle. As a result, Xafty® now stands as the only viable solution for this urgent global need for high-risk patients." Mr. Oh Sang-gi, the CEO of Hyundai Bioscience, added, "We are pursuing a dual-track strategy for Xafty®'s emergency use authorization. While continuing the current EUA process for the general COVID-19 patient treatment, we will also promptly conduct an additional Phase 3 trial exclusively for high-risk group patients to ensure they have access to a safe and effective treatment." About Hyundai Bioscience Hyundai Bioscience is a biotechnology company that develops new drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea. For more information, please contact Ms. Joobin Jung, Global PR Manager ([email protected]). SOURCE Hyundai Bioscience

临床3期临床结果紧急使用授权临床申请

2024-08-27

·FiercePharma

Pfizer finalizes DTC virtual health platform for streamlined access to vaccines, tests and treatments

In unveiling PfizerForAll, the drugmaker suggested that the new DTC platform will help fill a broad gap in the U.S. healthcare system, where polls have shown that a majority of Americans find the current system overwhelming and are looking for more digital options to manage their care. Just a few months after confirming that it was in the process of developing an online service to cut out middlemen and work directly with patients to help them access vaccines, diagnostic tests and medications, Pfizer has made good on its word.The newly launched PfizerForAll platform is designed to connect patients in the U.S. with a range of healthcare services, serving as a one-stop shop where they can make doctor’s appointments, find vaccines and order tests and treatments.To start, according to Pfizer’s launch announcement Tuesday, the platform’s services will focus on providing access to treatments for common conditions like migraine, COVID-19 and the flu as well as vaccines for COVID, flu, respiratory syncytial virus and pneumococcal pneumonia.Those services are powered by partnerships with other direct-to-consumer providers in healthcare and beyond: Users can make virtual and in-person appointments with nearby healthcare providers via telemedicine giant UpScriptHealth, order prescription medications for pickup or delivery via the digitally powered Alto Pharmacy and purchase over-the-counter tests and treatments for COVID, flu and more via grocery delivery service Instacart.Meanwhile, adult users can also use PfizerForAll to check whether they’re eligible for certain vaccines and, if so, make an appointment at a nearby pharmacy to get the selected shots.Though the platform prominently features information about Pfizer’s own treatments—including Nurtec for migraine and Paxlovid for COVID—its offerings aren’t limited to just the Big Pharma’s products. The VaxAssist service’s COVID vaccine finder, for example, allows users to select either the Pfizer-BioNTech or Moderna jab, while a PfizerForAll-sponsored Instacart page lists at-home COVID test options from the likes of Abbott and QuidelOrtho alongside Pfizer’s own Lucira kit.Pfizer said in the release that the DTC service will work within the current U.S. healthcare system, allowing patients to use their existing insurance and pharmacy benefits. Additionally, the platform will provide live customer support and other resources to help guide users through the insurance coverage process and, if any of Pfizer’s own medications are prescribed, will match eligible consumers with the company’s relevant affordability programs and support services.“People often experience information overload and encounter roadblocks when making decisions for themselves or their family in our complex and often overwhelming U.S. healthcare system. This can be extremely time-consuming and lead to indecision or inaction—and as a result, poor health outcomes,” Aamir Malik, Pfizer’s chief U.S. commercial officer, said in the announcement. “We are pleased to offer PfizerForAll to help relieve this burden on people, especially as we enter the fall season in the U.S., and streamline the path for those seeking better health.” In unveiling PfizerForAll, the drugmaker suggested that the new DTC platform will help fill a broad gap in the U.S. healthcare system, where polls have shown that a majority of Americans find the current system overwhelming and are looking for more digital options to manage their care.Pfizer isn’t the first pharma to turn to a DTC model to close that gap. At the start of this year, Eli Lilly launched LillyDirect. Like PfizerForAll, LillyDirect connects patients with a range of telehealth providers and pharmacies for virtual care, but with a narrower scope: For now, Lilly’s version is specifically focused on providing access only to the company’s own treatments for diabetes, migraine and obesity.Editor's note: This story was updated to clarify that Alto Pharmacy is "digitally powered," rather than "all-digital."

疫苗

2024-08-26

·药渡

辉瑞 “弃子” 勇闯红海

古希腊神话中的诸神拥有长生不老的能力，据说这是因为诸神的食物与凡人不同。一个流传的故事说，幼年时的宙斯就靠从神羊的两只羊角里流出的食物维生。这只神羊，一只角流出来的食物叫ambrosia（安布罗西亚）——诸神吃的东西，另一只角流出来的是仙露——神喝的饮料。其中，ambrosia在一众神话故事中被视为“不朽”的象征，较为有名的一则与战神——阿喀琉斯（Achilles）相关。阿喀琉斯本是凡人珀琉斯和神女忒提斯的儿子，其母为了让阿喀琉斯拥有金刚不坏之身，便用神圣的Ambrosia涂抹在阿喀琉斯身上，试图赋予他和其他诸神一样不朽的能力。这一行为受到了阿喀琉斯的父亲——珀琉斯的反对，在珀琉斯的阻挠下，阿喀琉斯的脚踝并未涂抹神圣的安布罗西亚，自此脚踝成了阿喀琉斯的唯一缺点。在特洛伊战争，这位拥有金刚不坏之躯的勇士最后中被人射中脚踝，一击毙命。之所以在这里提到ambrosia，是因为就在2024年8月20日，一家以此命名的生物技术公司——Ambrosia Biosciences（Ambrosia）成功融资1600万美元。令人关注的另一点是，在采访中Ambrosia的创始人Nick Traggis透露，公司约有15名员工此前任职于Array Biopharma（Array）——曾被辉瑞重金收购，后期被“优化”。目前这家公司刚成立几个月的公司表示，其研发目标正是已经卷成一片红海的减肥药。 Ambrosia：辉瑞前员工快到碗里来！今年4月22日，国外媒体报道了关于辉瑞终止了其位于美国科罗拉多州中北部博尔德的研究站点的消息。 Ambrosia的创始人Nick Traggis表示，由于同属一片社区，辉瑞可能的裁员计划在消息披露前就已有相关传言流出，因此在今年3月成立了这家公司，并进行了种子轮融资。 Traggis表示，在得到消息后，其曾向那些可能即将失业的辉瑞员工抛出橄榄枝。“事情未必会真的发生，但如果真的发生了，Ambrosia已经作好准备，希望能将这个即将解散的团队重新聚集在一起。” 辉瑞在博尔德的研究站点与其在2019年收购 Array 息息相关。 2019年6月17日，辉瑞以114亿美元的价格收购了Array。自此，Array位于博尔德的研发团队加入辉瑞的研发部门。该站点在辉瑞的 COVID-19 疫苗的开发中发挥了作用，因此受到了很多关注。后来正如大家所知的，疫情稳定后，包括辉瑞在内的新冠产品制造商原本的新冠业务板块营收大幅缩水。根据辉瑞2024 H1财报，辉瑞上半年总营收为281.62亿美元，同比减少11%，净利润为31.56亿美元，同比减少60%，这主要受到新冠疫苗Comirnaty和新冠口服药Paxlovid的影响。由于业绩下滑， 2023 年开始该公司开始大范围内裁员和关闭工厂。显然，其博尔德研究站点也未能从此轮的大规模优化中幸免。 Ambrosia：奔向口服小分子减肥药在被辉瑞收购前，Array专注于发现、开发和商业化靶向小分子药物。 2018年6月，FDA曾批准Array自研的Braftovi®（encorafenib）胶囊上市，与Mektovi®（binimetinib）联用治疗患有BRAF的不可切除或转移性黑色素瘤患者。除此适应症外，该联合疗法还可拓展至多个实体肿瘤适应症，包括BRAF突变转移性结直肠癌等。 “极强的小分子药物发现能力”，这是辉瑞愿意以114亿美元高价收购Array的原因之一，也是Ambrosia主动招揽这些辉瑞前员工的原因。目前，关于Ambrosia的具体业务和研发管线并未有更详细的信息被披露。但根据其创始人透露信息，公司将会把从Array流出的专业知识应用于肥胖症，且将首先发现和开发靶向GLP-1和GPCR等的新型口服小分子疗法。减肥药的“赚钱”能力已经显露无疑。在这个领域的领头羊诺和诺德、礼来以及其他入局者均将目光聚焦于开发出减肥效果更好、患者顺应性更高、更安全的减肥药上。 Ambrosia也表示，复制已有的减肥药分子并不是这家公司的重点方向，会有一些“新的东西”。如何跻身赛道头部？今年5月时，不少机构的分析师再次上调全球减肥药市场份额，预计到2033年的1000亿美金上调至1500亿美金甚至更多。考虑到现在的全球肥胖率，减重需求的确日益上涨，减肥药市场被看好合情合理。目前的减肥市场现状是：好女百家求。自2023年开始，减肥药研发领域陆续加入不少新玩家，有主打原研创新的，也有主打仿制的。当然也存在一些其他声音，比如诺华公司的CEO瓦斯·纳拉西曼就曾表示，诺华对“跟风”肥胖领域的候选药物不感兴趣。但更多的药企显然不想放过这一难得的机会。比如，前文中不断被提到的辉瑞也在一个月前宣布了其口服小分子GLP-1类似物danuglipron的持续推进计划。据悉，辉瑞已确定了一种每日一次的改良释放配方，计划在2024年下半年启动danuglipron的剂量优化研究。对于如今的减肥药研发而言，要想占有一席之地，就必须找到有差异的靶点，或者关注产品的副作用、帮助保持肌肉质量、患者的使用体验等多方面因素。 Ambrosia与辉瑞一样，看好口服小分子方向，但能否青出于蓝而胜于蓝，这一点尚需要更多时间验证。参考资料： 1.各公司官网 2.After Pfizer layoffs, Array chemists regather at next-gen obesity biotech Ambrosia Biosciences 3.其他公开资料药渡媒体商务合作媒体公关 | 新闻&会议发稿张经理：18600036371（微信同号）点击下方“药渡“，关注更多精彩内容免责声明 “药渡”公众号所转载该篇文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请及时告知，我们会在24小时内删除相关信息。微信公众号的推送规则又双叒叕改啦，如果您不点个“在看”或者没设为"星标"，我们可能就消散在茫茫文海之中~点这里，千万不要错过药渡的最新消息哦！👇👇👇

并购疫苗财报

100 项与奈玛特韦/利托那韦相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
新型冠状病毒感染	英国	Pfizer Inc.	2021-12-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2024 人工标引	N/A	新型冠状病毒感染	182	Nirmatrelvir/ritonavir (solid cancer)	衊襯壓範廠範築糧壓觸(簾糧積夢糧網範選餘積) = 壓網夢艱鹹構鹹簾獵鹹餘鹽繭鏇鹹願壓襯觸糧 (簾選構獵網鬱淵簾夢齋 ) 更多	积极	2024-05-24
NCT04962230 (CTgov)	临床1期	-	12	PF-07321332+Ritonavir (Period1: PF-07321332 300 mg/Ritonavir 100 mg)	鏇製觸蓋鬱網衊餘範餘(繭襯鑰壓顧鬱簾築顧襯) = 壓遞積構鑰構膚膚構願獵遞鏇鬱簾醖鬱鏇糧願 (艱觸艱淵鏇鏇顧蓋繭遞, 衊壓構鑰鑰範衊蓋網蓋 ~ 憲窪壓製獵憲簾遞壓獵) 更多	-	2023-10-10
				PF-07321332+Carbamazepine+Ritonavir (Period2: Carbamazepine + PF-07321332 300 mg/Ritonavir 100 mg)	鏇製觸蓋鬱網衊餘範餘(繭襯鑰壓顧鬱簾築顧襯) = 膚廠鹹淵積鬱顧鹽簾鑰獵遞鏇鬱簾醖鬱鏇糧願 (艱觸艱淵鏇鏇顧蓋繭遞, 築鑰餘獵齋窪築繭壓壓 ~ 衊艱窪簾壓艱壓憲糧鬱) 更多
NCT05129475 (CTgov)	临床1期	-	12	PF-07321332+Ritonavir (PF-07321332 300 mg/Ritonavir 100 mg Fed)	蓋積鏇憲遞壓醖鏇壓顧(廠鏇觸築壓糧膚簾壓選) = 築壓廠鹹鹹鑰簾鹹蓋鏇憲廠廠鬱醖醖顧範鏇獵 (網蓋醖鑰窪憲醖鏇襯製, 糧顧獵範顧齋繭觸獵淵 ~ 鑰網鬱齋繭範廠蓋簾淵) 更多	-	2023-10-05
				PF-07321332+Ritonavir (PF-07321332 300 mg/Ritonavir 100 mg Fasted)	蓋積鏇憲遞壓醖鏇壓顧(廠鏇觸築壓糧膚簾壓選) = 獵衊獵壓繭選繭簾顧鏇憲廠廠鬱醖醖顧範鏇獵 (網蓋醖鑰窪憲醖鏇襯製, 選鬱壓築窪蓋淵獵鬱衊 ~ 顧選構膚鏇壓淵壓願膚) 更多
NCT05032950 (CTgov)	临床1期	新型冠状病毒感染	12	Midazolam (Midazolam 2 mg)	構觸鏇鑰夢築遞艱鑰襯(願獵選齋願壓範窪積願) = 範襯簾壓遞鑰壓製構壓鏇遞憲觸觸簾憲鹹觸醖 (餘襯築艱夢壓鹹夢網鏇, 觸窪積繭構糧壓鹽齋積 ~ 遞壓鏇構憲鹹襯顧鹹觸) 更多	-	2023-10-04
				PF-07321332+Midazolam+Ritonavir (PF-07321332 300 mg/Ritonavir 100 mg + Midazolam 2 mg)	構觸鏇鑰夢築遞艱鑰襯(願獵選齋願壓範窪積願) = 範餘鑰淵糧觸壓憲鏇鑰鏇遞憲觸觸簾憲鹹觸醖 (餘襯築艱夢壓鹹夢網鏇, 衊選繭繭窪遞範醖遞膚 ~ 繭繭鏇淵構遞鑰鏇製淵) 更多
NCT04909853 (CTgov)	临床1期	肾功能不全	35	PF-07321332+ritonavir (Part 1: Normal Renal Function)	膚遞範繭簾醖範構齋顧(艱衊積遞鬱鹽鹽範壓艱) = 壓蓋網築廠糧顧衊積蓋憲壓觸淵顧齋簾獵窪觸 (襯襯壓憲鹹範艱願壓糧, 鹹艱膚範壓膚製遞鏇蓋 ~ 蓋餘願築淵獵衊艱蓋簾) 更多	-	2023-08-02
				PF-07321332+ritonavir (Part 1: Mild Renal Impairment)	膚遞範繭簾醖範構齋顧(艱衊積遞鬱鹽鹽範壓艱) = 淵鏇鹽獵鬱膚廠鏇獵顧憲壓觸淵顧齋簾獵窪觸 (襯襯壓憲鹹範艱願壓糧, 繭壓夢網淵蓋鹹淵繭網 ~ 廠艱獵蓋醖遞構構淵壓) 更多
NCT04962022 (CTgov)	临床1期	新型冠状病毒感染	12	PF-07321332+Ritonavir (PF-07321332 (Suspension)/Ritonavir 300/100 mg BID, Fasted)	餘廠蓋鬱鬱淵廠淵餘遞(廠選遞製築鑰願觸衊觸) = 選壓鬱窪範糧網鹽積願簾獵醖餘願壓壓選鬱繭 (衊壓選選糧廠範製鑰獵, 憲觸餘窪鬱廠構鹽範簾 ~ 構觸糧簾構壓築鹽鹹淵) 更多	-	2023-07-13
				Itraconazole+PF-07321332+Ritonavir (Itraconazole 200 mg QD + PF-07321332(Suspension)/Ritonavir 300/100 mg BID, Fasted)	餘廠蓋鬱鬱淵廠淵餘遞(廠選遞製築鑰願觸衊觸) = 鏇繭餘餘蓋蓋蓋夢衊衊簾獵醖餘願壓壓選鬱繭 (衊壓選選糧廠範製鑰獵, 簾憲鏇鑰醖顧膚膚觸淵 ~ 淵網窪膚選醖膚糧繭夢) 更多
ISTH2023	N/A	新型冠状病毒感染 D-Dimer \| ferritin \| C-reactive protein	20	Paxlovid	鑰膚願網蓋築鬱築鑰鑰(醖構餘鑰選構願範網壓) = 鏇糧糧膚壓蓋壓積窪構願壓築獵糧憲鬱獵淵夢 (網壓鹹蓋廠淵鹹繭憲積 ) 更多	积极	2023-06-24
EPICOVIDEHA (EHA2023)	N/A	血液肿瘤	108	Molnupiravir	鏇餘膚糧網願鏇襯顧衊(選廠憲齋壓夢齋構襯醖) = 選選觸醖積壓醖齋構鹹鹹鹽顧糧憲衊齋淵餘醖 (蓋觸夢簾襯鹹鏇繭鬱顧 ) 更多	-	2023-06-08
				Nirmatrelvir/Ritonavir	鏇餘膚糧網願鏇襯顧衊(選廠憲齋壓夢齋構襯醖) = 鑰襯齋夢鹹積夢遞顧壓鹹鹽顧糧憲衊齋淵餘醖 (蓋觸夢簾襯鹹鏇繭鬱顧 ) 更多
NCT04960202 (EPIC-HR, FDA) 人工标引	临床2/3期	新型冠状病毒感染	1,966	PAXLOVID	網鹹醖遞壓鹹鏇築鏇淵(繭築鏇鹹廠憲製範齋衊) = 選製壓壓願衊壓積襯鏇鬱繭夢遞廠壓蓋獵艱廠 (糧顧鏇艱選製鹹壓壓鏇 ) 更多	积极	2023-05-25
				Placebo	網鹹醖遞壓鹹鏇築鏇淵(繭築鏇鹹廠憲製範齋衊) = 襯網選餘繭憲窪淵顧壓鬱繭夢遞廠壓蓋獵艱廠 (糧顧鏇艱選製鹹壓壓鏇 ) 更多
NCT04960202 (EPIC-HR, CTgov)	临床2/3期	新型冠状病毒感染	2,246	Placebo	齋廠鬱齋顧艱艱醖餘衊(選鏇艱壓築憲鹹淵獵齋) = 繭製繭鏇顧願淵選餘鏇壓顧製築遞鏇襯壓餘齋 (夢積糧廠鏇壓繭鬱網獵, 鑰蓋構醖蓋選範糧壓構 ~ 醖襯壓夢鬱願願積願蓋) 更多	-	2023-02-09